Biopure Swot Analysis
Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new blood substitute based treatment for managing patients' oxygen requirements in a broad range of potential medical applications. The main issue that is plaguing Biopure is how the possible launch of Oxyglobin will affect the future launch and pricing strategies of Hemopure, which could provide a larger return for their investment.
Biopure's strength lies in their ability to market its blood substitute products for both human and animal use. Biopure has a product that has been approved by the FDA for animal use and has the intellectual property that will allow them to protect their product for two to five years before other competition can enter the market using similar technology. The company's main weakness is that it has not received FDA approval for Hemopure, and there are other competitors that could beat Biopure to the market with their own version of a blood......
View the rest of this paper...
Approximate Word Count: 880
Approximate Pages: 4 (250 words per double-spaced page)
Why should you join Frat Files?
- - It's safe, secure, and private.
- - Instant access to over 100,000 papers. New papers are added hourly.
- - Fast and reliable customer support.
Similar Essays
-
Biopure Swot Analysis
biopure swot analysis. Biopure's two products, Hemopure for human use,
and Oxyglobin for animal veterinary use, both represented ... -
Biopure
... The Decision pending with Carl Rausch the CEO of Biopure was if ... 4) Assumptions and
Uncertainties: 5) Action Steps: Exhibit 1: SWOT Analysis Strengths Weakness ...
Frat Files
Members
Information
